Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
MYCB1 Group B.V. logo — MYCB1 Group B.V. produces, and distributes GMP-grade cannab...

MYCB1 Group B.V.

MYCB1 Group B.V. produces, and distributes GMP-grade cannabinoid medicines via its German subsidiary, MYCB1 GmbH

Founded 2017 The Netherlands The Netherlands 18 employees Debt Financing Total: $3.11M AI, Health Care +2

General Information

Company Name MYCB1 Group B.V.
Founded Year 2017
Location The Netherlands The Netherlands
Employees 18
Industries AI, Health Care, Medical Devices +1
Funding Stage Debt Financing
Business Model B2B, Marketplace, Platform
Revenue Model Product Sales, Service Fee, Marketplace Fee
Social

BounceWatch is an independent company data service, not affiliated with MYCB1 Group B.V.. To contact MYCB1 Group B.V., visit mycb1.de.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MYCB1 Group B.V. compare?

A PDF of MYCB1 Group B.V. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MYCB1 Group B.V. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MYCB1 Group B.V.

MYCB1 Group B.V. is a Dutch pharmaceutical group that stands out for its specialization in cannabinoid-based medical solutions. Its subsidiary, MYCB1 GmbH in Steinheim, Westphalia, serves as the core of its operations, focusing on the production and distribution of GMP-grade cannabinoid medicines.

Founded in 2017, MYCB1 Group B.V. operates within a diverse range of industries including AI, Health Care, Medical Devices, and Pharmaceutical. The company leverages its expertise to develop prescription-only medications that cater to a global market.

Headquartered in The Netherlands, the company last secured a financing round of €250.00K through debt financing on 01 October 2021. Despite the lack of specific investor names, this financial backing could illustrate investor confidence in their innovative approach to cannabinoid therapeutics.

Business keywords: Cannabinoid Medicines, GMP-grade Pharmaceuticals, Pharmaceutical Manufacturing, Prescription-only Medications, Personalized Medicine, Digital Health Solutions, Generative AI, Real-World Evidence, Patient-Centric Healthcare, Data-Driven Health Decisions, Health Technology Scale-up, Evidence-Based Healthcare, Software Engineering in Health, Pharmacy Operations

Services & Products

regulatory infrastructure support
GMP/GDP operations
storage services
distribution services
brand retention services
curated product portfolio

Target Customers

pharmaceutical companies cannabis brands healthcare distributors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing €250.00K -
01 Oct 2021
Funding Round €1.34M -
01 Mar 2021
Non Equity Assistance €1.51M -
01 Jan 2020

MYCB1 Group B.V. Alternatives & Competitors

View All Alternatives
MYCB1 Group B.V. vs
CurifyLabs
CurifyLabs Finland

Automated compounding of personalized medicine

Series A
33 employees
Biotechnology, Health Care
MYCB1 Group B.V. vs
Savana
Savana Spain

Deep Real World Evidence: EHRs reuse via AI I Top 10 HEOR solutions providers in Europe 2023 I The...

Venture round
129 employees
AI, Health Care
MYCB1 Group B.V. vs
moveUP - digital therapies
moveUP - digital therapies Belgium

Follow us to stay updated on our findings on value-based health care derived from our growing set of...

Merged
26 employees
Biotechnology, Digital Health
View all alternatives

FAQ About MYCB1 Group B.V.

MYCB1 Group B.V. produces, and distributes GMP-grade cannabinoid medicines via its German subsidiary, MYCB1 GmbH
MYCB1 Group B.V. was founded in 2017.
MYCB1 Group B.V. is headquartered in The Netherlands.
MYCB1 Group B.V. operates in AI, Health Care, Medical Devices and Pharmaceutical. Its work centres on Cannabinoid Medicines, GMP-grade Pharmaceuticals, Pharmaceutical Manufacturing and Prescription-only Medications. Its customers include pharmaceutical companies, cannabis brands and healthcare distributors.
MYCB1 Group B.V. has a B2B, Marketplace and Platform business model. Its revenue comes from Product Sales, Service Fee and Marketplace Fee.
MYCB1 Group B.V. has approximately 18 employees.
MYCB1 Group B.V. has completed 3 funding rounds, raising a total of $3.11M. The latest funding stage is Debt Financing.
MYCB1 Group B.V. offers: regulatory infrastructure support, GMP/GDP operations, storage services, distribution services, brand retention services, curated product portfolio.
Top alternatives and competitors to MYCB1 Group B.V. include CurifyLabs, Savana, moveUP - digital therapies, Smartway Pharmaceuticals, Henry Meds. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MYCB1 Group B.V. and CurifyLabs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MYCB1 Group B.V., https://bouncewatch.com/company/mycb1-group-bv, updated 15 August 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout